Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 1.00 |
| ▸ | HTR3B | O95264 | 2/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)Zacopride SCHEMBL5387843 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL5373467 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL29567897 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7280998 | 0.99 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7281576 | 0.99 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL667580 | 0.99 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7280994 | 0.99 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL9598323 | 0.98 | MAPK1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL29389976 | 0.98 | MAPK1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7288008 | 0.94 | HTR3A (0.88) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2032 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116211847-A | Application of saururus chinensis ketone in preparation of medicine for preventing and/or treating irritable bowel syndrome | 四川省医学科学院·四川省人民医院 | 2023-06-06 | — | — | CN | claimed |
| US-11571397-B2 | Compositions and methods for treating seizure-induced sudden death | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-02-07 | — | — | US | claimed |
| US-20220313686-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF OPIOID ANTAGONISTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-10-06 | — | — | US | claimed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | claimed |
| EP-4013390-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF OPIOID ANTAGONISTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2022-06-22 | — | — | EP | claimed |
| CN-114599355-A | Method for treating psychological and cerebral diseases | 马里兰大学巴尔的摩分校 | 2022-06-07 | — | — | CN | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20210338647-A1 | Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-04 | — | — | US | claimed |
| EP-0327335-A1 | Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency | SYNTHELABO (FR) | 1989-08-09 | — | — | EP | claimed |
| EP-0311724-A1 | Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1989-04-19 | — | — | EP | claimed |
| EP-0306345-A2 | 2-Alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | claimed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | claimed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | claimed |
| EP-0240180-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs | SYNTHELABO (FR) | 1987-10-07 | — | — | EP | claimed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | claimed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | claimed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | claimed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | claimed |